Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China

被引:7
|
作者
Li, Heng
Xiong, Wenjie
Liu, Huimin
Yi, Shuhua
Yu, Zhen
Liu, Wei
Lyu, Rui
Wang, Tingyu
Zou, Dehui
Li, Zengjun
Qiu, Lugui
机构
[1] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Dept Lymphoma & Myeloma, Inst Hematol, Tianjin 300020, Peoples R China
关键词
17p deletion; chronic lymphocytic leukemia (CLL); fluorescent in situ hybridization (FISH); del17p in CLL; HIGH-DOSE METHYLPREDNISOLONE; LRF CLL4 TRIAL; RITUXIMAB; THERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; ABNORMALITIES; ALEMTUZUMAB; ABERRATIONS;
D O I
10.21147/j.issn.1000-9604.2017.02.09
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia (CLL) and a 17p deletion (17p-) and identify the predictive factors within this subgroup. Methods: The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 11q22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p-were retrospectively collected and analyzed. Results: The overall response rate (ORR) in patients with a 17p- was 56.9%, and patients with a high percentage of 17p-(defined as more than 25% of cells harbouring a 17p-) had a lower ORR. The median overall survival (OS) in patients with a 17p-was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality (median 162.0 months, P<0.001). Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase (LDH), B symptoms, unmutated IGHV and a high percentage of 17p-. Conclusions: These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.
引用
收藏
页码:156 / 165
页数:10
相关论文
共 50 条
  • [31] Outcome and Prognostic Factors of 17p Deleted Multiple Myeloma Patients
    Kull, Miriam
    Teleanu, Veronica
    Hayde, Daniela
    Wildbihler, Katrin
    Harsdorf, Stephanie
    Bunjes, Donald
    Liebisch, Peter
    Langer, Christian
    BLOOD, 2014, 124 (21)
  • [32] Outcome and prognostic factors of 17p deleted multiple myeloma patients
    Kull, M.
    Teleanu, V
    Schwarzwaeldr, P.
    Wildbihler, K.
    Hayde, D.
    Kolmus, S.
    Greiner, A.
    Liebisch, P.
    Langer, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 18 - 18
  • [33] EVALUATION OF 243 PATIENTS WITH DELETION 17P CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB: A CROSS-STUDY ANALYSIS OF TREATMENT OUTCOMES
    Jones, J.
    Coutre, S.
    Byrd, J. C.
    Furman, R.
    Hillmen, P.
    Mato, A.
    Osterborg, A.
    Tam, C.
    Stilgenbauer, S.
    Wierda, W.
    Heerema, N.
    Eckert, K.
    Clow, F.
    Zhou, C.
    Chu, A.
    James, D.
    O'Brien, S.
    HAEMATOLOGICA, 2016, 101 : 150 - 150
  • [34] Prognostic Impact of TP53 Mutation in Combination with Chromosome 17p Deletion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Yun, Seongseok
    Sandoval-Sus, Jose
    Knepper, Todd C.
    Teer, Jamie
    Chavez, Julio C.
    Pinilla-Ibarz, Javier
    BLOOD, 2017, 130
  • [35] Treatment Outcome and Prognostic Factors of Korean Patients with Chronic Lymphocytic Leukemia: Multicenter Retrospective Study
    Choi, Yunsuk
    Lee, Jung-Hee
    Jung, Chul Won
    Kim, Jin Seok
    Kim, Inho
    Park, Silvia
    Cheong, June-Won
    Park, Seonyang
    Kim, Sung-Yong
    Lee, Mark Hong
    BLOOD, 2014, 124 (21)
  • [36] Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study
    Choi, Yunsuk
    Lee, Jung-Hee
    Jung, Chul Won
    Jo, Jae-Cheol
    Kim, Jin Seok
    Kim, Inho
    Park, Silvia
    Cheong, June-won
    Park, Sang-Hyuk
    Kim, Sung-Yong
    Lee, Hong-Ghi
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (01): : 194 - +
  • [37] TREATMENT AND 17P DELETION TESTING PATTERNS IN COMMUNITY PRACTICE FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES
    Kapustyan, T.
    Keim, H.
    Meissner, B.
    Zhang, L.
    Jiang, D.
    HAEMATOLOGICA, 2017, 102 : 420 - 420
  • [38] Treatment patterns and best response in a contemporary cohort of patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion
    Lamanna, Nicole
    Hurst, Deborah
    Latremouille-Viau, Dominick
    Ionescu-Ittu, Raluca
    Guerin, Annie
    Yim, Yeun Mi
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2015, 56 : 147 - 148
  • [39] Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL)
    Heerema, Nyla A.
    Muthusamy, Natarajan
    Ruppert, Amy S.
    Andritsos, Leslie A.
    Grever, Michael R.
    Jones, Jeffrey A.
    Maddocks, Kami
    Byrd, John C.
    BLOOD, 2013, 122 (21)
  • [40] Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p)
    Strati, Paolo
    Keating, Michael J.
    O'Brien, Susan Mary
    Ferrajoli, Alessandra
    Burger, Jan Andreas
    Faderl, Stefan
    Jain, Nitin
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)